Scancell released full-year results alongside a business update anchored by positive phase 2 melanoma data and a more straightforward path to registration. The company’s next-generation DNA vaccine iSCIB1+, combined with checkpoint inhibitors, delivered a reported 78% progression-free survival at 11 months in a defined HLA target population in the SCOPE trial, with pooled data across cohorts indicating 69% PFS at 22 months. Safety appeared favorable across more than 100 patients; iSCIB1+ has been selected as the lead program, and randomized studies are planned to begin in 2026. Early phase 2 signals from Moditope’s Modi-1 in head and neck cancer, a second antibody license to Genmab worth $6 million upfront with up to $630 million in milestones, and the creation of GlyMab Therapeutics as a wholly owned subsidiary, round out a strategy that mixes clinical momentum with partnering optionality. Cash stood at £16.9 million at April 30, 2025, with runway into the second half of 2026.
The strategic question is whether an off-the-shelf cancer vaccine can credibly reposition the first-line melanoma landscape already shaped by checkpoint doublets and, increasingly, individualized mRNA vaccines. Scancell’s bet is convenience and scalability: a -20°C-stable DNA construct that avoids lipid nanoparticles, delivered via a needle-free device, layered onto existing checkpoint regimens. If PFS gains versus historical ipilimumab plus nivolumab translate in randomized settings, this becomes a real challenge to the assumption that personalization is required to unlock vaccine-driven efficacy.
Timing matters. Melanoma is in flux as multiple modalities converge: checkpoint doublets in frontline disease, TIL therapies making inroads, and mRNA vaccines showing promise in adjuvant settings. An add-on DNA vaccine with broad HLA coverage for approximately 80% of late-stage patients could be attractive to oncologists seeking incremental efficacy without new toxicity burdens, and to patients for whom personalized manufacturing timelines are impractical. For payers, however, the calculus will hinge on more than PFS. An add-on price atop high-cost checkpoint combinations must be justified by the magnitude and durability of benefit, quality-of-life impact, and potential downstream offsets in subsequent therapy and resource use. An HLA-defined label will require clear testing workflows, Medical Affairs-led education, and potentially payer-aligned diagnostics strategies to avoid friction at the point of care.
For competitors, the signal is clear: the cancer vaccine race is not a single-lane personalized contest. Off-the-shelf platforms with credible data, manufacturability, and pragmatic delivery can compete on speed, scale, and cost. For big pharma, this is a window of opportunity for partnering. A checkpoint owner could seek to preserve franchise relevance by integrating iSCIB1+ into combination journeys and co-developing registrational trials, particularly as global evidence demands expand under the EU HTA Joint Clinical Assessment and as regulators show continued flexibility on PFS endpoints in metastatic settings.
The financing architecture is equally instructive. Scancell is using antibody out-licensing to Genmab and a dedicated GlyMab subsidiary to bring in non-dilutive capital and preserve strategic flexibility for its immunotherapy assets. With convertible notes still outstanding and pivotal trials ahead, further partnerships or creative financing will likely be needed to sustain the 2026 registrational timelines.
The following inflection points arrive quickly: additional SCOPE cohort data and Modi-1 readouts in the fourth quarter, pre-IND interactions in 2025, and protocol clarity for randomization. The industry will be watching one issue above all: can Scancell convert a promising translational profile into a payer-ready, first-line melanoma regimen that reshapes value expectations for cancer vaccines in the checkpoint era?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
